Published in J Virol on January 01, 1998
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol (1998) 2.47
A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol (2000) 2.00
Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol (1999) 1.64
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol (1999) 1.58
Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol (2000) 1.55
Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther (2009) 1.47
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46
Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol (1999) 1.32
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle. J Virol (1998) 1.25
Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol (1999) 1.13
Translation is not required To generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells. J Virol (2000) 1.12
Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO J (2000) 1.11
Design of a trans protease lentiviral packaging system that produces high titer virus. Retrovirology (2007) 1.05
Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS One (2009) 1.03
The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events. Genet Vaccines Ther (2004) 0.95
Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev (2016) 0.95
Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol (2000) 0.94
Methods for gene transfer to the central nervous system. Adv Genet (2014) 0.88
Transduction of terminally differentiated neurons by avian sarcoma virus. J Virol (2004) 0.87
Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp Neurol (2007) 0.86
Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol (2009) 0.84
Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemother (2003) 0.83
Lentiviral vector design using alternative RNA export elements. Retrovirology (2007) 0.82
Locus control region of the human CD2 gene in a lentivirus vector confers position-independent transgene expression. J Virol (2001) 0.82
Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses. Curr Pharm Biotechnol (2011) 0.82
Production of lentiviral vectors. Mol Ther Methods Clin Dev (2016) 0.82
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev. J Virol (2001) 0.81
Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene transfer vectors for high-level transgene expression. J Virol (2000) 0.81
Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods (2013) 0.79
Packaging cell lines for simian foamy virus type 1 vectors. J Virol (1999) 0.79
[Comparison of several viral vectors for gene therapy of corneal endothelial cells]. Ophthalmologe (2005) 0.78
The determination of importance of sequences neighboring the Psi sequence in lentiviral vector transduction and packaging efficiency. PLoS One (2012) 0.77
Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo. Mol Ther Nucleic Acids (2012) 0.76
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells. Biologics (2009) 0.76
Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system. Nat Commun (2017) 0.75
Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. J Occup Environ Med (2016) 0.75
Expression of exogenetic enhanced green fluorescent protein in rat endocranium through lentivirus infection. Int J Clin Exp Pathol (2015) 0.75
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (1989) 13.92
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res (1995) 7.08
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A (1992) 6.85
The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell (1989) 6.13
Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol (1989) 6.11
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65
Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A (1996) 3.07
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell (1993) 2.90
HIV accessory proteins: leading roles for the supporting cast. Cell (1995) 2.82
Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol (1992) 2.70
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol (1994) 2.18
Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol (1991) 2.15
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A (1993) 1.93
Tat is required for efficient HIV-1 reverse transcription. EMBO J (1997) 1.90
The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function. J Virol (1996) 1.85
Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J (1994) 1.78
The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol (1997) 1.78
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol (1995) 1.74
Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci U S A (1995) 1.64
Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest (1991) 1.64
Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. J Virol (1993) 1.57
Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol (1996) 1.49
Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol (1996) 1.46
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol (1995) 1.36
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A (1993) 1.29
Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci U S A (1996) 1.15
Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J Virol (1994) 1.12
Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol (1996) 1.06
A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol (1994) 1.05
Helper virus-free transfer of human immunodeficiency virus type 1 vectors. J Gen Virol (1995) 1.01
Rev/RRE-independent Mason-Pfizer monkey virus constitutive transport element-dependent propagation of SIVmac239 vectors using a single round of replication assay. Virology (1996) 1.00
Gene therapy in the United States: a five-year status report. Hum Gene Ther (1996) 0.94
Construction and characterization of a potent HIV-2 Tat transdominant mutant protein. J Acquir Immune Defic Syndr (1994) 0.90
A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res (1995) 7.08
Conservation of high efficiency promoter sequences in Saccharomyces cerevisiae. Nucleic Acids Res (1982) 5.90
Expression in Saccharomyces cerevisiae of human interferon-alpha directed by the TRP1 5' region. Nucleic Acids Res (1983) 4.01
HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell (1988) 3.36
Efficient synthesis of enzymatically active calf chymosin in Saccharomyces cerevisiae. Gene (1983) 3.25
Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast. Nature (1986) 3.07
Sequence variation in dispersed repetitive sequences in Saccharomyces cerevisiae. J Mol Biol (1981) 2.76
Replication in Saccharomyces cerevisiae of plasmid pBR313 carrying DNA from the yeast trpl region. Gene (1979) 2.73
A retrovirus-like strategy for expression of a fusion protein encoded by yeast transposon Ty1. Nature (1985) 2.68
Efficient expression of the Saccharomyces cerevisiae PGK gene depends on an upstream activation sequence but does not require TATA sequences. Mol Cell Biol (1986) 2.63
Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet (2001) 2.36
ARS binding factor 1 binds adjacent to RAP1 at the UASs of the yeast glycolytic genes PGK and PYK1. Nucleic Acids Res (1990) 2.31
Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol (1997) 2.24
The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins. Cell (1987) 2.23
Synthesis of a gene for the HIV transactivator protein TAT by a novel single stranded approach involving in vivo gap repair. Nucleic Acids Res (1988) 2.22
A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol (2000) 2.00
Characterization of human chromosomal DNA sequences which replicate autonomously in Saccharomyces cerevisiae. Nucleic Acids Res (1984) 1.93
HIV-1 TAT "activates" presynthesized RNA in the nucleus. Cell (1989) 1.89
Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J Virol (1994) 1.84
Regulated high efficiency expression of human interferon-alpha in Saccharomyces cerevisiae. EMBO J (1982) 1.84
Transcriptional control of the Saccharomyces cerevisiae PGK gene by RAP1. Mol Cell Biol (1989) 1.74
A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction. Cell (1990) 1.73
Characterisation of the DNA binding domain of the yeast RAP1 protein. Nucleic Acids Res (1990) 1.53
Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J Virol (1997) 1.48
The UAS of the yeast PGK gene contains functionally distinct domains. Nucleic Acids Res (1987) 1.46
Factors affecting heterologous gene expression in Saccharomyces cerevisiae. Gene (1985) 1.44
Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol (1996) 1.44
Mutants of Salmonella typhimurium responding to cysteine or methionine: their nature and possible role in the regulation of cysteine biosynthesis. J Gen Microbiol (1975) 1.43
The UAS of the yeast PGK gene is composed of multiple functional elements. Nucleic Acids Res (1988) 1.38
The expression of hybrid HIV:Ty virus-like particles in yeast. Nature (1987) 1.38
Blocking of Tat-dependent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity. Nature (1991) 1.36
Multiple control elements in the TRP1 promoter of Saccharomyces cerevisiae. Mol Cell Biol (1986) 1.34
Expression strategies of the yeast retrotransposon Ty: a short sequence directs ribosomal frameshifting. Nucleic Acids Res (1986) 1.33
Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J (1992) 1.32
The identification and high level expression of a protein encoded by the yeast Ty element. EMBO J (1984) 1.31
Mutagenesis analysis of the murine leukemia virus matrix protein: identification of regions important for membrane localization and intracellular transport. J Virol (1997) 1.28
The behaviour in ferrets of two closely related clones of influenza virus of differing virulence for man. Br J Exp Pathol (1976) 1.27
Real-time analysis of the transcriptional regulation of HIV and hCMV promoters in single mammalian cells. J Cell Sci (1995) 1.27
Multiple cis-active elements in the long control region of bovine papillomavirus type 1 (BPV-1). Nucleic Acids Res (1987) 1.27
The regulation of human immunodeficiency virus type-1 gene expression. Eur J Biochem (1996) 1.25
Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway. Nucleic Acids Res (1994) 1.24
Complete nucleotide sequence of a mouse VL30 retro-element. Mol Cell Biol (1988) 1.23
Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther (2007) 1.22
Upstream and downstream transcriptional control signals in the yeast retrotransposon, TY. Nucleic Acids Res (1988) 1.21
Variants within the yeast Ty sequence family encode a class of structurally conserved proteins. Nucleic Acids Res (1985) 1.18
A transcriptional activator is located in the coding region of the yeast PGK gene. Nucleic Acids Res (1987) 1.16
Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription. Nucleic Acids Res (1989) 1.15
The Ty transposon of Saccharomyces cerevisiae determines the synthesis of at least three proteins. Nucleic Acids Res (1985) 1.14
TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I. Nucleic Acids Res (1998) 1.14
Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunol (1993) 1.11
An immunological analysis of Ty1 virus-like particle structure. Virology (1995) 1.09
Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther (2005) 1.09
Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Ther (2003) 1.06
Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol (1996) 1.06
Characterization of the transcriptional potency of sub-elements of the UAS of the yeast PGK gene in a PGK mini-promoter. Nucleic Acids Res (1989) 1.04